.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
McKinsey
US Army
McKesson
Colorcon
Johnson and Johnson
Baxter
Argus Health
Deloitte
Accenture

Generated: September 26, 2017

DrugPatentWatch Database Preview

Gd Searle Llc Company Profile

« Back to Dashboard

What is the competitive landscape for GD SEARLE LLC, and what generic alternatives to GD SEARLE LLC drugs are available?

GD SEARLE LLC has forty-two approved drugs.

There are eight US patents protecting GD SEARLE LLC drugs.

There are ninety-four patent family members on GD SEARLE LLC drugs in thirty countries.

Summary for Applicant: Gd Searle Llc

Patents:8
Tradenames:37
Ingredients:25
NDAs:42
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gd Searle Llc
ARTHROTEC
diclofenac sodium; misoprostol
TABLET, DELAYED RELEASE;ORAL020607-001Dec 24, 1997ABRXYesNo► Subscribe► Subscribe► Subscribe
Gd Searle Llc
SYNAREL
nafarelin acetate
SPRAY, METERED;NASAL019886-001Feb 13, 1990RXYesYes► Subscribe► Subscribe► Subscribe
Gd Searle Llc
DEMULEN 1/50-28
ethinyl estradiol; ethynodiol diacetate
TABLET;ORAL-28016936-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Gd Searle Llc
LOMOTIL
atropine sulfate; diphenoxylate hydrochloride
TABLET;ORAL012462-001Approved Prior to Jan 1, 1982AARXYesYes► Subscribe► Subscribe► Subscribe
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-002Feb 26, 1996DISCNNoNo► Subscribe► Subscribe ► Subscribe
Gd Searle Llc
AMINOPHYLLIN
aminophylline
TABLET;ORAL002386-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Gd Searle Llc
INSPRA
eplerenone
TABLET;ORAL021437-001Sep 27, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
Gd Searle Llc
INSPRA
eplerenone
TABLET;ORAL021437-002Sep 27, 2002ABRXYesYes► Subscribe► SubscribeY► Subscribe
Gd Searle Llc
INSPRA
eplerenone
TABLET;ORAL021437-001Sep 27, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
Gd Searle Llc
POTASSIUM CHLORIDE
potassium chloride
INJECTABLE;INJECTION086219-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Gd Searle Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-002Feb 26, 1996► Subscribe► Subscribe
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-002Feb 26, 1996► Subscribe► Subscribe
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-001Feb 26, 1996► Subscribe► Subscribe
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-001Feb 26, 1996► Subscribe► Subscribe
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-002Feb 26, 1996► Subscribe► Subscribe
Gd Searle Llc
CYTOTEC
misoprostol
TABLET;ORAL019268-003Sep 21, 1990► Subscribe► Subscribe
Gd Searle Llc
CU-7
copper
INTRAUTERINE DEVICE;INTRAUTERINE017408-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Gd Searle Llc
TATUM-T
copper
INTRAUTERINE DEVICE;INTRAUTERINE018205-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Gd Searle Llc
INSPRA
eplerenone
TABLET;ORAL021437-002Sep 27, 2002► Subscribe► Subscribe
Gd Searle Llc
ARTHROTEC
diclofenac sodium; misoprostol
TABLET, DELAYED RELEASE;ORAL020607-001Dec 24, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for GD SEARLE LLC drugs

Drugname Dosage Strength Tradename Submissiondate
diclofenac sodium and misoprostol
Delayed-release Tablets50 mg/0.2 mg
ARTHROTEC
6/29/2009
diclofenac sodium and misoprostol
Delayed-release Tablets75 mg/0.2 mg
ARTHROTEC
11/28/2008
eplerenone
Tablets25 mg and 50 mg
INSPRA
9/27/2006

Non-Orange Book Patents for Gd Searle Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,534,089 Uniform drug delivery therapy► Subscribe
6,863,902 Immediate release eplerenone compositions► Subscribe
6,592,902 Controlled release eplerenone compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Gd Searle Llc Drugs

Country Document Number Estimated Expiration
Canada2249637► Subscribe
Eurasian Patent Organization200100951► Subscribe
Spain2207977► Subscribe
Czech Republic20011590► Subscribe
Canada2364169► Subscribe
European Patent Office1126880► Subscribe
Hungary224428► Subscribe
Norway20012782► Subscribe
South Africa200103632► Subscribe
Israel142911► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Gd Searle Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/031United Kingdom► SubscribePRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
2015000093Germany► SubscribePRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
C0026France► SubscribePRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220
12/008Ireland► SubscribePRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
00095Netherlands► SubscribePRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
C/GB95/010United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
C0055France► SubscribePRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
00C/027Belgium► SubscribePRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
80024Netherlands► SubscribePRODUCT NAME: GADOBEENZUUR,DESGEWENST IN DE VORM VAN EEN ZOUT MET EEN ALKA- LIMETAAL, AARDALKALIMETAAL, OF BASISCH GEPROTONEERD AMINOZUUR OF VAN EEN ALKYLAMMONIUM-, ALKANOLAMMONIUM- OF POLYHYDROXYAL- KYLAMMONIUMZOUT, IN HET BIJZONDER DIMEGLUMINI GADOBENAS; NAT. REGISTRATION NO/DATE: RVG 22324 19980706; FIRST REGISTRATION: GB PL 06099/0006 19970722
C/GB12/028United Kingdom► SubscribePRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Merck
Argus Health
Colorcon
McKesson
Citi
Novartis
Federal Trade Commission
Boehringer Ingelheim
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot